Format

Send to:

Choose Destination
See comment in PubMed Commons below
Med Sci (Paris). 2011 Jun-Jul;27(6-7):626-31. doi: 10.1051/medsci/2011276015. Epub 2011 Jul 1.

[CYLD deubiquitinase as a recurrent target in oncogenic processes].

[Article in French]

Author information

  • 1Institute of Genetics, University of Cologne, Cologne, Allemagne.

Abstract

CYLD deubiquitinase has been originally defined as a tumor suppressor based exclusively on genetic findings. Indeed, inactivation of CYLD in humans results in familial cylindromatosis and multiple trichoepithelioma, two pathologies characterized by the development of tumors originating specifically from the skin appendages. A set of recent publications has revealed that recurrent inactivation of CYLD occurs through diverse mechanisms in several forms of cancer, unequivocally confirming its tumor suppressor function. This property is associated with the critical role played by CYLD in negatively regulating several signaling pathway, among them the NF-κB signaling pathway.

© 2011 médecine/sciences - Inserm / SRMS.

PMID:
21718647
[PubMed - indexed for MEDLINE]
Free full text
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for EDP Sciences
    Loading ...
    Write to the Help Desk